Work

Going deep for drug discovery: an ocean to bedside approach to explore sub-seafloor microbes for the next generation of antibiotics.

Year: 2012

Type: article

Abstract: mediciNe & HealtH/RHode iSlaNd the world health organIzatIon haS identified antimicrobial resistance as one of the top three greatest threats to human health. Today, infections by methicillinresistant Staphylococcus aureus (MRSA) account for more deaths in US hospitals than both tuberculosis and HIV/AIDS combined. More than 60% of staph infections in intensive care units are due to drug resistant strains, and it is common to encounter those that lack sensitivity to multiple classes of drugs. In addition, pathogenic Escherichia coli and Klebsiella pneumoniae are increasingly found to produce an extended spectrum of enzymes that significantly decrease drug options for treating infections and often leave patients with limited to no antimicrobial treatment options. Regrettably, antimicrobial research and development is not keeping pace with rising drug resistance. There are currently no novel drugs in late stage development for the treatment of multidrug-resistant Gram-negative pathogens. Going deep for drug discovery: an ocean to Bedside Approach to Explore Sub-Seafloor Microbes for the Next Generation of antibiotics

Source: PubMed

Authors: Stephanie Forschner-Dancause, Kerry LaPlante, David C Smith, David C Rowley

Institution: University of Rhode Island

Language: English

Topic: Microbial Natural Products and Biosynthesis

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institutes of Health

Award: Exploiting deep ocean biology for biomedical discovery